Shanghai-based TYK Medicines has announced a partnership with WuXi STA, a subsidiary of WuXi AppTec (SHA: 603259), to enhance their collaboration in the field of Chemistry, Manufacturing, and Controls Development (CMC) services. According to the agreement, WuXi STA will serve as a strategic partner to TYK Medicines, offering one-stop services that include process development, clinical and commercial production of APIs and formulations, as well as the preparation of regulatory filings in both China and the US for TYK Medicines’ current and future pipeline products.
TYK Medicines: Innovating in Cancer Treatment with Kinase Inhibitors
TYK Medicines is dedicated to researching and developing new generation kinase inhibitors to address unmet clinical needs in cancer treatment. The company’s portfolio includes over ten innovative drugs at various stages, from preclinical candidate compounds to Phase III clinical trials. TYK Medicines has a history of collaboration with WuXi STA on multiple projects, which has covered research and development, production of APIs and formulations, and the drafting of Investigational New Drug (IND) application materials in China and the United States.
Expanding the R&D Pipeline and Collaboration
The decision to expand the R&D pipeline and deepen the collaboration between TYK Medicines and WuXi STA is based on the rapid progress achieved through their previous project cooperation. WuXi STA, a leading CRDMO enterprise, has a track record of success, having supported the approval of 38 innovative drugs for partners since 2017, with the supported new drugs launched across 105 countries worldwide.-Fineline Info & Tech
